BioCryst 製藥公司
MX ˙ BMV ˙ US09058V1035
SecurityMX:BCRX / BioCryst Pharmaceuticals, Inc.
InstitutionStifel Financial Corp
Latest Disclosed Ownership1,825,184 shares
Latest Disclosed Value $ 17,375,751
Stifel Financial Corp reports 0.04% increase in ownership of BCRX / BioCryst Pharmaceuticals, Inc.

On May 12, 2026 - Stifel Financial Corp filed a 13F-HR form disclosing ownership of 1,825,184 shares of BioCryst Pharmaceuticals, Inc. (MX:BCRX) valued at $17,375,751 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 1,824,517 shares of BioCryst Pharmaceuticals, Inc.. This represents a change in shares of 0.04% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,825,184 667 0.04 17,376 22.09 0.0037
2026-02-13 2025-12-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,824,517 1,525 0.08 14,231 2.85 0.0128
2025-11-12 2025-09-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,822,992 -296 -0.02 13,837 -15.30 0.0126
2025-08-14 2025-06-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,823,288 -13,691 -0.75 16,337 18.57 0.0159
2025-05-14 2025-03-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,836,979 -6,007 -0.33 13,777 -0.59 0.0146
2025-02-13 2024-12-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,842,986 -303 -0.02 13,859 -1.06 0.0144
2024-11-14 2024-09-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,843,289 -363 -0.02 14,009 22.95 0.0147
2024-08-13 2024-06-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,843,652 -284 -0.02 11,394 21.63 0.0128
2024-05-14 2024-03-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,843,936 -119 -0.01 9,367 -15.19 0.0107
2024-02-12 2023-12-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,844,055 36 0.00 11,046 -15.40 0.0139
2023-11-13 2023-09-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,844,019 -535 -0.03 13,056 0.54 0.0184
2023-08-14 2023-06-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,844,554 480 0.03 12,986 -15.57 0.0178
2023-05-12 2023-03-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,844,074 0 0.00 15,380 -27.35 0.0220
2023-02-13 2022-12-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,844,074 -2,100 -0.11 21,170 -8.99 0.0318
2022-11-14 2022-09-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,846,174 -3,850 -0.21 23,261 18.84 0.0381
2022-08-15 2022-06-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,850,024 -318 -0.02 19,573 -34.94 0.0306
2022-05-13 2022-03-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,850,342 818 0.04 30,086 17.45 0.0411
2022-02-14 2021-12-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,849,524 -830 -0.04 25,616 -3.66 0.0339
2021-11-15 2021-09-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,850,354 0 0.00 26,590 -9.11 0.0390
2021-08-13 2021-06-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,850,354 0 0.00 29,254 55.46 0.0438
2021-05-14 2021-03-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 1,850,354 -191,745 -9.39 18,818 23.70 0.0310
2021-02-12 2020-12-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 2,042,099 0 0.00 15,213 116.86 0.0271
2020-11-16 2020-09-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 2,042,099 0 0.00 7,015 -27.90 0.0144
2020-08-14 2020-06-30 13F BIOCRYST PHARMACEUTICALS COM 09058V103 2,042,099 -49,170 -2.35 9,730 132.66 0.0224
2020-05-14 2020-03-31 13F BIOCRYST PHARMACEUTICALS COM 09058V103 2,091,269 2,091,269 4,182 0.0115
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.